A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
about
Interventions for managing advanced liver disease in cystic fibrosisDigestive Enzyme Supplementation in Gastrointestinal DiseasesReview article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases.Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data.Ursodeoxycholic acid treatment of vanishing bile duct syndromes.Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.Managing liver failure.Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease.Cystic fibrosis-related liver disease: a single-center experience.Diagnostic approach to patients with cholestatic jaundice.Current and future anti-fibrotic therapies for chronic liver disease.Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal intestinal obstruction syndrome, and constipationCystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations.Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells.Ursodeoxycholic acid action on the transport function of the small intestine in normal and cystic fibrosis mice.Cystic fibrosis liver disease: to transplant or not to transplant?Bioequivalence of a new liquid formulation of ursodeoxycholic acid (Ursofalk suspension) and Ursofalk capsules measured by plasma pharmacokinetics and biliary enrichment.The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study.Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease.Gastrointestinal Manifestations of Cystic Fibrosis.Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy
P2860
Q24186697-7021B5D7-23A0-4497-83BC-6C9B46747E47Q28079538-86EACBD8-7A58-4DD3-85DB-CDEF1299C77DQ33723536-2BE4378C-12D6-4D17-9078-2CB31A95BD70Q33839732-42BBB75D-42C2-404B-96F4-DC5DEA0EA37CQ33866782-956CAE4D-8E65-4309-A6A7-35C879E95EDFQ34017604-2C3481F7-E77A-4295-8638-EE480CC00B1DQ35032212-86347C7B-6DFE-419E-BA6D-F1BFCAD5A830Q35272532-CAF216D9-BBC0-4118-844A-987C11E272EBQ35514538-A2137E82-099B-4CDB-A3A3-D87D26ED4FD7Q36396784-A9814AAB-7F48-46D2-8D1C-392BF6653779Q37317654-14531153-32B3-4179-B7FD-BDBF5C6372E5Q37850707-56221416-7843-49A8-AAB4-E712E62A4DD4Q38252636-927654BF-FAAA-45A5-9190-AC62603DA36CQ42515580-A8862A8D-4741-4C4C-BFCC-BF741BDAD2F9Q43815262-43B3FBD2-6418-42DA-9960-463FC6B2C615Q44558476-C24E96F7-5A86-45B2-BC3E-DCEBF42AF89BQ46383706-BA3F5BF5-A433-4C6F-8EB8-7206440FB3FEQ46884201-651A8422-AED5-420B-B44E-60C313EF3240Q47198958-E1C0F62A-E177-49CD-998F-1683F5B1B0E3Q49334378-08224C5A-20CB-4AF2-AA20-7486446C45E5Q53627194-5294FE80-4698-4F83-8E7D-9CB054B905EBQ57651838-825B53AD-9E70-4104-8CE3-EDFB7A3F0526
P2860
A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
A two-year prospective study o ...... osis-associated liver disease.
@en
A two-year prospective study o ...... osis-associated liver disease.
@nl
type
label
A two-year prospective study o ...... osis-associated liver disease.
@en
A two-year prospective study o ...... osis-associated liver disease.
@nl
prefLabel
A two-year prospective study o ...... osis-associated liver disease.
@en
A two-year prospective study o ...... osis-associated liver disease.
@nl
P2093
P356
P1433
P1476
A two-year prospective study o ...... osis-associated liver disease.
@en
P2093
Glaumann H
Lindblad A
Strandvik B
P304
P356
10.1002/HEP.510270126
P407
P577
1998-01-01T00:00:00Z